Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
by
Winters, Mark A.
, Holodniy, Mark
, Miller, Michael D.
, Shafer, Robert W.
, Kozal, Michael J.
, Lloyd, Robert M.
in
Acquired immune deficiency syndrome
/ AIDS
/ Antiretroviral agents
/ Antiretroviral drugs
/ Biology
/ Care and treatment
/ Cloning
/ Digital rights (Intellectual property)
/ DNA polymerases
/ Drug resistance
/ Drug Resistance, Viral - genetics
/ Failure
/ Genetic aspects
/ Highly active antiretroviral therapy
/ HIV
/ HIV Integrase - genetics
/ HIV Integrase Inhibitors - pharmacology
/ HIV Reverse Transcriptase - genetics
/ HIV-1 - drug effects
/ HIV-1 - enzymology
/ HIV-1 - genetics
/ Human immunodeficiency virus
/ Humans
/ Integrase
/ Medical research
/ Medicine
/ Molecular Sequence Data
/ Mutation
/ Open Reading Frames - genetics
/ Patients
/ Peptide Hydrolases - genetics
/ Protease
/ Protease inhibitors
/ Protease Inhibitors - pharmacology
/ Proteases
/ Proteinase inhibitors
/ Quinolones - pharmacology
/ RNA-directed DNA polymerase
2012
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
by
Winters, Mark A.
, Holodniy, Mark
, Miller, Michael D.
, Shafer, Robert W.
, Kozal, Michael J.
, Lloyd, Robert M.
in
Acquired immune deficiency syndrome
/ AIDS
/ Antiretroviral agents
/ Antiretroviral drugs
/ Biology
/ Care and treatment
/ Cloning
/ Digital rights (Intellectual property)
/ DNA polymerases
/ Drug resistance
/ Drug Resistance, Viral - genetics
/ Failure
/ Genetic aspects
/ Highly active antiretroviral therapy
/ HIV
/ HIV Integrase - genetics
/ HIV Integrase Inhibitors - pharmacology
/ HIV Reverse Transcriptase - genetics
/ HIV-1 - drug effects
/ HIV-1 - enzymology
/ HIV-1 - genetics
/ Human immunodeficiency virus
/ Humans
/ Integrase
/ Medical research
/ Medicine
/ Molecular Sequence Data
/ Mutation
/ Open Reading Frames - genetics
/ Patients
/ Peptide Hydrolases - genetics
/ Protease
/ Protease inhibitors
/ Protease Inhibitors - pharmacology
/ Proteases
/ Proteinase inhibitors
/ Quinolones - pharmacology
/ RNA-directed DNA polymerase
2012
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
by
Winters, Mark A.
, Holodniy, Mark
, Miller, Michael D.
, Shafer, Robert W.
, Kozal, Michael J.
, Lloyd, Robert M.
in
Acquired immune deficiency syndrome
/ AIDS
/ Antiretroviral agents
/ Antiretroviral drugs
/ Biology
/ Care and treatment
/ Cloning
/ Digital rights (Intellectual property)
/ DNA polymerases
/ Drug resistance
/ Drug Resistance, Viral - genetics
/ Failure
/ Genetic aspects
/ Highly active antiretroviral therapy
/ HIV
/ HIV Integrase - genetics
/ HIV Integrase Inhibitors - pharmacology
/ HIV Reverse Transcriptase - genetics
/ HIV-1 - drug effects
/ HIV-1 - enzymology
/ HIV-1 - genetics
/ Human immunodeficiency virus
/ Humans
/ Integrase
/ Medical research
/ Medicine
/ Molecular Sequence Data
/ Mutation
/ Open Reading Frames - genetics
/ Patients
/ Peptide Hydrolases - genetics
/ Protease
/ Protease inhibitors
/ Protease Inhibitors - pharmacology
/ Proteases
/ Proteinase inhibitors
/ Quinolones - pharmacology
/ RNA-directed DNA polymerase
2012
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
Journal Article
Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
2012
Request Book From Autostore
and Choose the Collection Method
Overview
Failure of antiretroviral regimens containing elvitegravir (EVG) and raltegravir (RAL) can result in the appearance of integrase inhibitor (INI) drug-resistance mutations (DRMs). While several INI DRMs have been identified, the evolution of EVG DRMs and the linkage of these DRMs with protease inhibitor (PI) and reverse transcriptase inhibitor (RTI) DRMs have not been studied at the clonal level. We examined the development of INI DRMs in 10 patients failing EVG-containing regimens over time, and the linkage of INI DRMs with PI and RTI DRMs in these patients plus 6 RAL-treated patients. A one-step RT-nested PCR protocol was used to generate a 2.7 kB amplicon that included the PR, RT, and IN coding region, and standard cloning and sequencing techniques were used to determine DRMs in 1,277 clones (mean 21 clones per time point). Results showed all patients had multiple PI, NRTI, and/or NNRTI DRMs at baseline, but no primary INI DRM. EVG-treated patients developed from 2 to 6 strains with different primary INI DRMs as early as 2 weeks after initiation of treatment, predominantly as single mutations. The prevalence of these strains fluctuated and new strains, and/or strains with new combinations of INI DRMs, developed over time. Final failure samples (weeks 14 to 48) typically showed a dominant strain with multiple mutations or N155H alone. Single N155H or multiple mutations were also observed in RAL-treated patients at virologic failure. All patient strains showed evidence of INI DRM co-located with single or multiple PI and/or RTI DRMs on the same viral strand. Our study shows that EVG treatment can select for a number of distinct INI-resistant strains whose prevalence fluctuates over time. Continued appearance of new INI DRMs after initial INI failure suggests a potent, highly dynamic selection of INI resistant strains that is unaffected by co-location with PI and RTI DRMs.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
Acquired immune deficiency syndrome
/ AIDS
/ Biology
/ Cloning
/ Digital rights (Intellectual property)
/ Drug Resistance, Viral - genetics
/ Failure
/ Highly active antiretroviral therapy
/ HIV
/ HIV Integrase Inhibitors - pharmacology
/ HIV Reverse Transcriptase - genetics
/ Human immunodeficiency virus
/ Humans
/ Medicine
/ Mutation
/ Open Reading Frames - genetics
/ Patients
/ Peptide Hydrolases - genetics
/ Protease
This website uses cookies to ensure you get the best experience on our website.